about
De novo generation of a transmissible spongiform encephalopathy by mouse transgenesisPrion gene haplotypes of U.S. cattleRepetitive immunization enhances the susceptibility of mice to peripherally administered prions.Plasmacytoid dendritic cells sequester high prion titres at early stages of prion infection.Immunomodulation for prion and prion-related diseases.Immunization with recombinant prion protein leads to partial protection in a murine model of TSEs through a novel mechanismCould immunomodulation be used to prevent prion diseases?Prions and their lethal journey to the brain.Antiprion prophylaxis by gene transfer of a soluble prion antagonist.High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.Therapeutic approaches for prion and Alzheimer's diseases.The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB PerspectiveChemical and biophysical insights into the propagation of prion strains.Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculationCells and prions: a license to replicate.A closer look at prion strains: characterization and important implications.DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge.A seeding based cellular assay of tauopathy.Processing of the bovine spongiform encephalopathy-specific prion protein by dendritic cellsCell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes.Copaxone interferes with the PrP Sc-GAG interaction.Introduction to Prion Disorders
P2860
Q30485527-10554451-2370-421F-934F-C084758BB5C2Q33263049-F6BFAEA3-9D07-43E4-BC96-918854357728Q33506629-9FD5C7D4-2D04-4799-8AB4-FCEFECACFE7DQ34167920-03CB806D-20E8-4F1A-AA21-F76B8ECA3D51Q34565644-CB8C9128-7E04-4478-9FC4-03B5A76B9A1FQ34648779-A4C2C67E-DC5F-44FE-AC66-85C3F7340813Q35875915-11148CCE-3346-49CB-9823-080A69F9F93EQ36389302-6D28C906-5654-4733-BE1D-F4BA2324F417Q36579822-D1696A95-6D7C-423F-9609-B3FB50F2D4F6Q36776046-0E784446-4E93-49F6-86EB-8B0D0B88846BQ36872884-0A86C307-3A8A-439C-982A-5DC67ECEF9AAQ37055497-0AC69EA3-85A4-4067-916D-F6C4737B7E51Q37104203-218CDDEE-EBB8-4726-986B-CE7AAA9390C7Q37293239-C47096C3-D6B9-45BA-944F-0F0B763F7131Q37520006-DD0781AB-0D17-4E65-AD2D-BCECB16736DFQ38077404-C2139B53-FA5F-45D8-8EAC-75F7B55EE5E6Q38761934-47396FB0-5D4C-4FDC-B289-B7957F0B7069Q41830631-AEF323F4-BCAA-469F-9D5F-12E7C436F396Q42066262-8E741671-968A-45D2-B41F-5C3DB9D990A8Q42432218-F777AADE-9F88-488A-BD43-3142950CBCD6Q51795714-9D1D7B74-AF01-4A59-8641-3131CB68528AQ57083613-66BEF121-9DEC-43A7-B39F-0CF7DD9C795C
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antiprion immunotherapy: to suppress or to stimulate?
@ast
Antiprion immunotherapy: to suppress or to stimulate?
@en
type
label
Antiprion immunotherapy: to suppress or to stimulate?
@ast
Antiprion immunotherapy: to suppress or to stimulate?
@en
prefLabel
Antiprion immunotherapy: to suppress or to stimulate?
@ast
Antiprion immunotherapy: to suppress or to stimulate?
@en
P2860
P356
P1476
Antiprion immunotherapy: to suppress or to stimulate?
@en
P2093
Christina J Sigurdson
P2860
P304
P356
10.1038/NRI1437
P577
2004-09-01T00:00:00Z